Laboratory of Bacteriology, Nice University Hospital, Nice, France. Professor Raymond Ruimy (M.D., Ph.D.) is a professor of clinical bacteriology at the medical school of the University of Côte d’Azur (UCA), Nice, France. Since 2012, he has headed the laboratory of bacteriology at Centre Hospitalier Universitaire (CHU), Nice. He is also a clinical researcher at the National Institute for Health and Medical Research in France (Inserm) on the “Microbial Virulence and Inflammatory Signaling” team at the Mediterranean Center for Molecular Medicine (C3M). During his academic training, he was trained in bacterial phylogeny and evolution (University of Paris 6). He has been an associate professor of clinical bacteriology at the CHU Bichat-Claude Bernard (University of Paris 7). He has worked in the field of bacterial resistance to antibiotics in the One Health context. Since 2017, he has focused his fundamental research on the mechanisms involved in the host-pathogen interaction during invasive infections by emerging pathogens such as Bacillus cereus and his clinical research on the different approaches to reduce the antimicrobial susceptibility turnaround time for patients with bacteremia.
Laboratory of Bacteriology, Nice University Hospital, Nice, France. Professor Raymond Ruimy (M.D., Ph.D.) is a professor of clinical bacteriology at the medical school of the University of Côte d’Azur (UCA), Nice, France. Since 2012, he has headed the laboratory of bacteriology at Centre Hospitalier Universitaire (CHU), Nice. He is also a clinical researcher at the National Institute for Health and Medical Research in France (Inserm) on the “Microbial Virulence and Inflammatory Signaling” team at the Mediterranean Center for Molecular Medicine (C3M). During his academic training, he was trained in bacterial phylogeny and evolution (University of Paris 6). He has been an associate professor of clinical bacteriology at the CHU Bichat-Claude Bernard (University of Paris 7). He has worked in the field of bacterial resistance to antibiotics in the One Health context. Since 2017, he has focused his fundamental research on the mechanisms involved in the host-pathogen interaction during invasive infections by emerging pathogens such as Bacillus cereus and his clinical research on the different approaches to reduce the antimicrobial susceptibility turnaround time for patients with bacteremia.